MBG453
MBG453 is a drug used to treat Myelodysplastic Syndromes, Acute Myeloid Leukemia, Advanced Malignancies, and other conditions. MBG453 is being actively studied in 10 studies; no studies for this drug have been completed so far.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Investigative Site | Andrew Mark Brunner, MD |
| Massachusetts General Hospital | Duke University Medical Center | |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | MD Anderson Cancer Center/University of Texas MD Anderson |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Not yet recruiting
- Myelodysplastic Syndromes
- MBG453
- Boston, Massachusetts
- +2 more
2021-03-28
Mar 28, 2021N
Recruiting
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- HDM201
- +2 more
- Durham, North Carolina
- +9 more
2022-03-23
Mar 23, 2022N
Active, not recruiting
- Leukemia
- +7 more
- Decitabine
- +3 more
- Boston, Massachusetts
- +10 more
2021-10-14
Oct 14, 2021N
Active, not recruiting
- Advanced Malignancies
- MBG453
- +2 more
- Baltimore, Maryland
- +13 more
2022-03-18
Mar 18, 2022S
Recruiting
- Glioblastoma Multiforme
- MBG453
- Stanford, California
- +1 more
2022-04-01
Apr 1, 2022N
Recruiting
- Acute Myeloid Leukemia
- MBG453
- +2 more
- San Francisco, California
- +27 more
2022-03-31
Mar 31, 2022N
Withdrawn
- Primary Myelofibrosis
- +4 more
- MBG453
- +3 more
- (no location specified)
2021-03-02
Mar 2, 2021N
Recruiting
- Myelodysplastic Syndrome (MDS)
- MBG453
- +3 more
- Chandler, Arizona
- +17 more
2022-03-23
Mar 23, 2022N
Active, not recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
- Duarte, California
- +46 more
2022-02-01
Feb 1, 2022N
Recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
- Columbus, Ohio
- +8 more
2022-02-21
Feb 21, 2022N
Active, not recruiting
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- MBG453
- +2 more
- Yuma, Arizona
- +148 more
2022-03-07
Mar 7, 2022